Device and method for intra-bronchial provision of a therapeutic agent

Abstract
The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. A device includes a flow control member for placement in an air passageway communicating with a lung portion, and when deployed in the air passageway inhibits a therapeutic agent distal of the control member from moving proximal of the control member, and includes the therapeutic agent associated with the flow control member. The control member may inhibit movement of the therapeutic agent by limiting airflow, and may include a one-way valve limiting exhalation of air from the lung portion. The control member may include a flexible membrane impervious to air flow, or a separator arranged to inhibit the movement of the therapeutic agent. The control member may include at least one anchor, and the anchor may be releasable from the air passageway for removal of the intra-bronchial device.
Description
BACKGROUND OF THE INVENTION

There is a continuing need for improved minimally invasive delivery of therapeutic agents to all portions of the respiratory system, particularly the lungs, bronchi and bronchioli, blood vessels, and lymphatic system. There is also a continuing need for improved minimally invasive access to lung tissue and structures.


The airways in the lungs anatomically constitute an extensive network of conduits that reach all lung areas and lung tissues. The airways have extensive branching that distally communicates with the parenchyma alveoli where gas exchange occurs, and proximally with the trachea and atmosphere (air). Because of the physiological characteristics of the airways, a therapeutic agent placed in bronchi and bronchioli may be delivered focally, localized, or systemically depending on the agent and the manner in which it is placed.


Historically, there has been a limited use of airways for delivery of therapeutic agents, diagnostic procedures, and instrumentation for invasive procedures. The airways have successfully been used for delivery of certain small particle therapeutic agents, such as inhalers for asthma, administration of gas anesthesia, and for introduction of certain visual diagnostic tools in conjunction with a bronchoscope. Through the bronchoscope, a limited number of invasive procedures are now being performed, including biopsies and removal of foreign objects.


Treatment of certain lung diseases and conditions would benefit from targeted intra-bronchial delivery of therapeutic agents into the involved regions, particularly those associated with the lungs such as pneumonia and lung cancer. Treatment would be further benefited if the therapeutic agent is generally confined to the involved regions. For example, treatment of a disease such as pneumonia will benefit by being able to deliver an antibiotic to the specific lung region involved. Furthermore, treatment of lung cancer may benefit from non-invasive brachytherapy. However, the full potential use of the airways for delivery of therapeutic agents and invasive procedures has not been realized because current technology is not able to isolate selected portions of the airways and/or lung tissue where therapeutic agents or procedures are to be delivered.


In view of the foregoing, there is a need in the art for a new and improved device, system, and method for isolating selected portions of airways without adversely effecting lung function or structure while allowing delivery of a therapeutic agent, or instrumentation. However, no such device, system, or method presently exists. Aspects of the present invention are directed to providing such an improved device and method.


SUMMARY OF THE INVENTION

The present invention includes an intra-bronchial device, system, and method for providing a therapeutic agent to a patient. The invention provides an intra-bronchial device including a member arranged for placement in an air passageway, and a therapeutic agent associated with the member and arranged for provision to a patient. The member may be further arranged for inhibiting the therapeutic agent from moving proximal of the control member. The intra-bronchial device may further include at least one anchor that retains the intra-bronchial device within the air passageway when the anchor is deployed, and at least one anchor may be releasable from the air passageway for removal of the intra-bronchial device.


The invention also provides an assembly including a therapeutic agent arranged for intra-bronchial delivery into an air passageway of a patient, and a flow control member arranged for placement in the air passageway and inhibiting the therapeutic agent from moving proximal of the control member. The flow control member may be arranged to allow the therapeutic agent to be associated with the flow control member after the flow control member is placed in the air passageway. The flow control member may be arranged to allow the therapeutic agent to be placed into the air passageway distal of the flow control member after the flow control member is placed in the air passageway.


The invention further provides an intra-bronchial device for maintaining a therapeutic agent within an air passageway. The device includes a flow control member arranged for placement in the air passageway and inhibiting the therapeutic agent from moving proximal of the control member, and the therapeutic agent. The control member may inhibit movement of the therapeutic agent by limiting flow from the air passageway. The control member may inhibit movement of the therapeutic agent by limiting flow into the air passageway, which limitation may be by limiting mucociliary transport from the air passageway. The control member may include a one-way valve. The one-way valve may permit inhalation of air into the air passageway, or permit exhalation of air from the air passageway. The control member may include a flexible membrane impervious to air flow. The flexible membrane may be arranged in cooperation with a wall of the air passageway to form a one-way valve permitting airflow from the air passageway, or a one-way valve permitting airflow into the air passageway. The control member may include a separator arranged to inhibit the movement of the therapeutic agent while allowing movement of air. The molecules of the therapeutic agent may be associated with molecules larger than air molecules, and the separator arranged to inhibit movement of the associated molecules while allowing movement of air molecules. The control member may include a semi-permeable membrane arranged to retain the therapeutic agent distal of the control member while permitting air and water molecules to be exhaled. The control member may limit airflow from the air passageway sufficiently to maintain inflation of a lung portion communicating with the air passageway. The control member may allow airflow from the air passageway sufficiently to prevent over-inflation of the lung portion. The control member may further include at least one anchor that retains the intra-bronchial device within the air passageway when the anchor is deployed, and at least one anchor may be releasable from the air passageway for removal of the intra-bronchial device. The control member may be further arranged to automatically terminate the inhibiting of movement by the therapeutic agent. The automatic termination may be provided by deterioration of the control member, or by dissolution of the control member.


The control member may be further arranged to permit mucociliary transport from the air passageway. The therapeutic agent may be associated with at least a portion of the control member. The therapeutic agent may overlie at least a portion of the airflow control member, may be imbedded in at least a portion of the airflow control member, may be absorbed in at least a portion of the airflow control member, and/or may be co-mixed with at least a portion of the airflow control member. The control member further includes an absorptive member and the therapeutic agent is absorbed by the absorptive member. The control member may include a cavity, and the therapeutic agent carried in the cavity. The cavity may include an absorptive member, and the therapeutic agent absorbed by the absorptive member. The cavity may included a cover having an orifice. The therapeutic agent may be one of antimicrobial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.


The invention still further provides a system for intra-bronchially providing a therapeutic agent to a patient. The system includes an intra-bronchial device including a flow control device arranged for placement in an air passageway, and when deployed, limits flow from the air passageway sufficiently to inhibit a therapeutic agent distal of the control member from moving proximal, and an introducer that introduces the therapeutic agent in the lung portion distal of the airflow control member.


The invention yet still further provides a method for providing a therapeutic agent to a patient. The method may include the steps of delivering a therapeutic agent to a lung portion, and inhibiting movement of the therapeutic agent from the lung portion. The inhibiting step may include the further step of limiting airflow from the lung portion to inhibit therapeutic agent distal of the control member from moving proximal. The method may include the further step of maintaining an inflation of the lung portion. The method may include the further step of maintaining a collapse of the lung portion. The delivering step may be performed with one intra-bronchial device and the inhibiting step is performed with another intra-bronchial device. The method may include the further step of performing the delivering step again. The inhibiting step may include the further step of implanting an intra-bronchial device in an air passageway in communication with the lung portion. The delivery step may include providing the therapeutic agent to the intra-bronchial device. The method may include the further step of terminating the inhibition of movement. The therapeutic agent may be one of antimicrobial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.


The invention also provides an intra-bronchial device for providing a therapeutic agent to a patient. The device including means for delivering a therapeutic agent into an air passageway of the patient, and means for intra-bronchially inhibiting movement of the therapeutic agent from the air passageway. The movement may be inhibited by limiting exhalation from the air passageway, by limiting inhalation into the air passageway, and/or by limiting movement of mucus from the air passageway.





BRIEF DESCRIPTION OF THE DRAWINGS

The features of the present invention which are believed to be novel are set forth with particularity in the appended claims. The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken in conjunction with the accompanying drawings, in the several figures of which like referenced numerals identify identical elements, and wherein:



FIG. 1 is a sectional view of a healthy respiratory system;



FIG. 2 is a perspective view of the bronchial tree detailing the upper right lung lobe;



FIG. 3 illustrates an initial step in providing a therapeutic agent to a patient that includes placing an intra-bronchial device in an air passageway using a catheter or bronchoscope, in accordance with the invention;



FIG. 4 illustrates a further step in placing a flow control member of the intra-bronchial device in a bronchial sub-branch using a catheter or a bronchoscope;



FIG. 5 illustrates an intermediate step where the flow control member has been inserted in the air passageway;



FIG. 6 illustrates a final step in inserting a flow control member of the intra-bronchial device;



FIG. 7 is a longitudinal sectional view illustrating releasing a therapeutic agent 105 distal of control member 90;



FIG. 8 is a longitudinal sectional view illustrating an intra-bronchial device placed in an air passageway for providing a therapeutic agent to a patient where the therapeutic agent is associated with a control member, in accordance with the invention;



FIG. 9 is a longitudinal sectional view illustrating an intra-bronchial device placed in an air passageway for providing a therapeutic agent to a patient, the control member of the intra-bronchial device having a cavity for carrying the therapeutic agent, in accordance with the invention;



FIG. 10 illustrates a control member similar to FIG. 9 with a cover having an orifice to regulate release of the therapeutic agent, in accordance with the invention;



FIG. 11 illustrates an intra-bronchial device for providing a therapeutic agent with a control member having a one-way valve, in accordance with the invention;



FIG. 12 illustrates the one-way valve of FIG. 11 in an open configuration;



FIG. 13 is a longitudinal sectional view illustrating the intra-bronchial device of FIG. 12 placed in an air passageway;



FIG. 14 is a longitudinal sectional view illustrating an alternative embodiment of the intra-bronchial device of FIG. 11 having a valving mechanism arranged to open when the air pressure in the lung portion reaches a predetermined level and to allow an exhalation airflow to prevent over inflation of the lung portion, in accordance with the invention;



FIG. 15 illustrates a side view of an anchored intra-bronchial device for providing a therapeutic agent, in accordance with the invention;



FIG. 16
a illustrates the device of FIG. 15 placed in an air passageway with an orientation that permits inhalation airflow 128 and inhibits exhalation flow, in accordance with the invention;



FIG. 16
b illustrates the device of FIG. 15 with an orientation that permits exhalation airflow 129 and inhibits inhalation air flow, in accordance with the invention; and



FIG. 17 illustrates an assembly of a plurality of intra-bronchial devices for providing a therapeutic agent and a flow control member for inhibiting movement of the therapeutic agent proximally, all placed in an air passageway branch, in accordance with the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the following detailed description of exemplary embodiments of the invention, reference is made to the accompanying drawings that form a part hereof. The detailed description and the drawings illustrate specific exemplary embodiments by which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. It is understood that other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the present invention. The following detailed description is therefore not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims.


Throughout the specification and claims, the following terms take the meanings explicitly associated herein unless the context clearly dictates otherwise. The meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.” Referring to the drawings, like numbers indicate like parts throughout the views. Additionally, a reference to the singular includes a reference to the plural unless otherwise stated or inconsistent with the disclosure herein. Additionally, throughout the specification, claims, and drawings, the term “proximal” means nearest the trachea, and “distal” means nearest the alveoli.



FIG. 1 is a sectional view of a healthy respiratory system. The respiratory system 20 resides within the thorax 22 that occupies a space defined by the chest wall 24 and the diaphragm 26.


The respiratory system 20 includes trachea 28; left mainstem bronchus 30 and right mainstem bronchus 32 (primary, or first generation); and lobar bronchial branches 34, 36, 38, 40, and 42 (second generation). FIG. 1 also illustrates segmental branches 44, 46, 48, 49, and 50 (third generation). Additional sub-branches are illustrated in FIG. 2. The respiratory system 20 further includes left lung lobes 52 and 54 and right lung lobes 56, 58, and 60. Each bronchial branch and sub-branch communicates with a different portion of a lung lobe, either the entire lung lobe or a portion thereof. As used herein, the term “air passageway” is meant to denote either a bronchi or bronchioli, and typically means a bronchial branch of any generation.


A characteristic of a healthy respiratory system is the arched or inwardly arcuate diaphragm 26. As the individual inhales, the diaphragm 26 straightens to increase the volume of the thorax 22. This causes a negative pressure within the thorax. The negative pressure within the thorax in turn causes the lung lobes to fill with air. When the individual exhales, the diaphragm returns to its original arched condition to decrease the volume of the thorax. The decreased volume of the thorax causes a positive pressure within the thorax, which in turn causes exhalation of the lung lobes.


Another characteristic of the respiratory system is the mucus flow from the lungs, or mucociliary transport system. Many pollution particles are inhaled as a person breathes, and the air passageways function as a very effective filter. The mucociliary transport system functions as a self-cleaning mechanism for all air passageways, including the lungs. The mucociliary transport system is a primary method for mucus clearance from distal portions of the lungs, and further constitutes a primary immune barrier for the lungs. The surface of air passageways is formed with respiratory epithelium (or epithelial membrane), which is covered with cilia and coated with mucus. As part of the mucociliary transport system, the mucus entraps many inhaled particles and moves them toward the larynx 28. The mucociliary transport system includes the metachronal ciliary beat of cilia on the respiratory epithelium that moves a continuous carpet of mucus and entrapped particles from the distal portions of the lungs past the larynx 28 and to the pharynx for expulsion from the respiratory system. The mucociliary transport system will also function as a self-clearing mechanism removing therapeutic agents placed in a lung portion and entrapped by the mucus. Additional description of the mucociliary transport system is provided in INTRA-BRONCHIAL OBSTRUCTING DEVICE THAT PERMITS MUCUS TRANSPORT filed May 9, 2002, application Ser. No. 10/143,353, which is owned by the Assignee, and which is incorporated herein by reference.



FIG. 2 is a perspective view of the bronchi emphasizing the upper right lung lobe 56. In addition to the bronchial branches illustrated in FIG. 1, FIG. 2 illustrates subsegmental bronchial branches 80, 82, 84, 86, 88, and 89 (fourth generation) providing air circulation to superior right lung lobe 56. The fifth- and sixth-generation bronchial branches are illustrated, but not given reference numbers.


The air passageways branch out, much like the roots of a tree. The bronchial segments branch into six generations or orders, and the bronchioles branch into approximately another three to eight generations or orders. Typically, each generation has a smaller diameter than its predecessor. The inside diameter of a generation varies depending on the particular bronchial branch, and further varies between individuals. For example, a typical lobar bronchus 42 (third generation) providing air circulation to the upper right upper lobe 56 has an internal diameter of approximately 1 cm. A typical segmental bronchi 48 (fourth generation) has an internal diameter of approximately 4 to 7 mm. The fifth and sixth generations (no reference numbers) are each proportionately smaller. The bronchial segments include annular ligaments and irregularly located cartilages that provide structure and resilience. The cartilages become increasingly sparse as the bronchial segments become smaller in diameter. The bronchioles do not have ligaments and cartilages. Furthermore, the inside diameters of air passageways is not static. They expand when a person inhales and contract when a person exhales.



FIGS. 3-7 illustrate a series of steps in providing a therapeutic agent to a patient, in accordance with the invention. FIG. 3 illustrates an initial step that includes placing an intra-bronchial device in an air passageway 50 using a catheter or bronchoscope. The invention disclosed herein is not limited to use with the particular method illustrated herein, and may be used in any air passageway or body lumen. Catheter 70 may be used alone to perform the insertion, may be extended from a bronchoscope, or used in conjunction with a bronchoscope. For purposes of this description, the insertion will be described with reference to only the catheter 70. Provision of a therapeutic agent is initiated by feeding a conduit, such as a catheter 70 down the trachea 28, into the right mainstem bronchus 32, into the bronchial branch 42 and into and terminating within the sub-branch 50. The sub-branch 50 is the air passageway that communicates with the lung portion 66 to be treated. The catheter 70 is preferably formed of flexible material such as polyethylene. Also, the catheter 70 is preferably preformed with a bend 72 to assist the feeding of the catheter from the right mainstem bronchus 32 into the bronchial branch 42, or could be deformed to conform to different curvature and angles of a bronchial tree.



FIG. 4 illustrates a further step in placing a flow control member 90 of the intra-bronchial device in a bronchial sub-branch 50 using a catheter or a bronchoscope. The control member 90 may be formed of resilient or collapsible material to enable the control member 90 to be fed through the conduit 70 in a collapsed state. A stylet 92 is used to push the control member 90 to the end 77 of the catheter 70 for inserting the control member 90 within the air passageway 50 adjacent to the lung portion 66 to be provided with the therapeutic agent.



FIG. 5 illustrates an intermediate step where the flow control member 90 has been inserted in air passageway 50, in accordance with the invention. Flow control member 90 has been pushed from the end 77 of the catheter 70 and expanded upon placement in the air passageway 50 to limit exhalation airflow and mucus flow (mucociliary transport) from the lung portion 66. This causes the lung portion 66 to be maintained in an expanded state. Because the exhalation airflow and the mucus flow (mucociliary transport) are limited, any therapeutic agent distal of the flow control member 90 will be inhibited from moving proximal of control member 90 and substantially confined to the lung portion 66 for provision of therapy.



FIG. 6 illustrates a final step in inserting a flow control member 90 of the intra-bronchial device, in accordance with the invention. The catheter 70 and the stylet 92 are being withdrawn from the patient, leaving the expanded flow control member 90 in air passageway 50.


The control member 90 may be any shape and composed of any material suitable for accomplishing its purpose. Possible shapes include spherical, cylindrical, oval, and conical. For example, control member 90 may be a conical shaped plug arranged to inhibit proximal movement of a therapeutic agent by sealing air passageway 50 against proximal flow of air and mucus. Control member 90 may be a solid member, a composition of materials, or a membrane that retains a shape or is carried on a frame. More specifically, the control member 90 has an outer dimension 91, and when expanded, enables contact with an air passageway inner dimension 51. The contact may be arranged in any manner to inhibit a therapeutic agent distal of the control member 90 from moving proximal to control member 90. As used in this specification, including the description and claims, the meaning of word “inhibit” and its derivatives, such as “inhibiting,” include reducing, diminishing, hindering, restraining, preventing, precluding, or prohibiting, unless otherwise indicated.


The intra-bronchial device is described in this specification, including the detailed description and the claims, in terms of limiting flow from a lung portion communicating with an air passageway. In some lungs, a portion of a lung may receive air from collateral air passageways. Controlling the airflow or mucociliary transport in one of the collateral air passageways may reduce the flow from the lung portion communicating with that air passageway, but may not completely control flow from the lung portion.



FIG. 7 is a longitudinal sectional view illustrating releasing a therapeutic agent 105 distal of control member 90, in accordance with the invention. In this embodiment, control member 90 generally has conical configuration, and may be hollow. More specifically, the control member 90 includes a periphery that renders it generally circular at its base, referred to herein as generally circular base 94. The control member 90 further includes a circumferential, generally conical sidewall 96 that extends from the outer periphery of generally circular base 94. The sidewall 96 has an exterior perimeter surface 98 that defines the outer periphery 91 of the control member 90. The control member 90 is arranged so that the outer periphery 91 of its exterior perimeter surface 98 contacts the air passageway inner dimension 51 of bronchial wall 100 to form a seal that limits air and/or mucus from moving past control member 90. The degree of inhibition may be varied by changing the structure of the control member 90.


Once the control member 90 is paced in the air passageway 50, a final step includes releasing the therapeutic agent 105 distal of the control member 90. Catheter 70 may be used to discharge therapeutic agent 105, or another thin catheter arranged for delivery of the therapeutic agent 105 may be used. The tip 77 of catheter 70 is guided between the exterior perimeter surface 98 and the bronchial wall 100, and advanced until tip 77 is distal of control member 90. The therapeutic agent 105 is released from the tip 77, and the catheter 70 is withdrawn from the patient. Additional doses of the therapeutic agent 105 may be administered by again placing a delivery catheter in the air passageway 50 and releasing additional therapeutic agent 105 distal of the control member 90.


In an alternative embodiment, the therapeutic agent 105 may be released first, and the control member 90 then placed in the air passageway 50 in position to inhibit movement of the therapeutic agent 105. In a further alternative embodiment, the control member 90 may be made of a self-sealing, pierceable material, such as a membrane, and the tip 77 arranged to pierce through the control member 90 and discharge the therapeutic agent 105 distal of the control member 90. In yet a further embodiment, the control member 90 may include an absorbable material, and the tip 77 arranged to discharge the therapeutic agent 105 into the absorbable material for release from the absorbable material distal of the control member 90.


In another embodiment, control member 90 may include a plurality of longitudinal ribs (not shown) on the outer peripheral surface 91. When the control member 90 is placed in the air passageway 50, the ribs and the interior wall of the air passageway define at least one peripheral flow pathway. The dimensioning and spacing of the longitudinal ribs may be selected to define the size of the peripheral flow pathway, and the degree to which airflow and/or mucociliary transport are inhibited. The larger a flow pathway, the less a flow will be limited.


In a still further alternative embodiment, the control member 90 is arranged to automatically terminate inhibition of proximal movement of the therapeutic agent 105. The inhibition may be automatically terminated by a dissolving, deteriorating, or other structural characteristic that causes the control member 90 to terminate forming a seal with the air passageway wall 100 without any outside act or step being taken. For example, all or a portion of the control member 90 may be made from a foam material arranged to dissolve or deteriorate after a predetermined length of time. Alternatively, all or a portion of control member 90 may be made from a sugar that will dissolve after a predetermined length of time. By way of further example, control member 90 may be arranged to dissolve or deteriorate after several days in the air passageway 50. This could allow treatment of localized pneumonia by isolating the involved lung portion with the control member 90. An antibiotic agent suitable for treating pneumonia may be placed in the lung portion 66, and retained in the lung portion by control member 90 for several days. After that period of time, the control member 90 would automatically deteriorate or dissolve, and be removed from the air passageway 50 by absorption, mucociliary transport, coughing, or some other mechanism without outside action. This would terminate the isolation and return the lung portion to normal functioning.


The term “therapeutic agent” is broadly used in this specification, including the description and claims, and includes anything presented for treatment, curing, mitigating, or preventing deleterious conditions in humans and animals. The term “therapeutic agent” also includes substances and agents for combating a disease, condition, or disorder of a patient, and includes drugs, diagnostics, and instrumentation.


“Therapeutic agent” also includes anything used in medical diagnosis, or in restoring, correcting, or modifying physiological functions. The term “therapeutic agent” may also mean a medicant or a medicine.


The therapeutic agent is selected according to the treatment objective and biological action desired. General classes of therapeutic agents include anti-microbial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.


The therapeutic agent may be selected from any class suitable for the therapeutic objective. For example, if the objective is treating a disease or condition associated with lungs such as acute or chronic pneumonia, the therapeutic agent may include antibiotics such as penicillin, ceftriaxone, tobramycin, vancomycin. By way of further example, if the desired treatment objective is treatment of cancer in lung or nearby tissue, the therapeutic agent may include radioactive material in the form of radioactive seeds providing radiation treatment directly into the tumor or close to it. Further, the therapeutic agent may be selected or arranged to provide therapeutic activity over a period of time.



FIG. 8 is a longitudinal sectional view illustrating an intra-bronchial device placed in an air passageway 50 for providing a therapeutic agent 105 to a patient, where the therapeutic agent 105 is associated with a control member 90, in accordance with the invention. For purposes of clarity in the specification and drawings, embodiments of the invention are generally illustrated with control member 90 as the only element of the intra-bronchial device. Alternative embodiments of an intra-bronchial device according to an aspect of the invention may include additional elements, such as structural members, anchors, and other members.


In accordance with a broad aspect of the present invention, the therapeutic agent 105 may be associated with the control member 90 of an intra-bronchial device in any manner known in the art suitable for release or provision to the patient. An embodiment of the invention is arranged to release of therapeutic agent 105 distal of the intra-bronchial device for providing focal and systemic treatments. Other embodiments are arranged to provide the therapeutic agent 105 to the tissue contact area between the intra-bronchial and the wall of the air passageway 100. FIG. 8 illustrates an embodiment where the therapeutic agent 105 is directly carried by or associated with the intra-bronchial device for release and provision to the patient. Alternatively, the therapeutic agent may be carried by or associated with another element that is coupled to the control member 90 as illustrated in FIGS. 15 and 16. The therapeutic agent 105 may be associated with the control member 90 in many different ways. It may be carried on proximal, distal, or both proximal and distal portions of the device as may be required by the intended therapeutic action and limitations of the selected therapeutic agent. FIG. 8, for example, illustrates an embodiment where therapeutic agent 105 overlies the surface of generally circular base 94 of control member 90. If the control member 90 is a membrane or generally hollow structure, the therapeutic agent 105 may be associated by overlayment on any suitable surface or surfaces, including an interior surface, or by another member coupled to the control member 90.


Therapeutic agent 105 may be associated with all or any portion of the control member 90 in any manner known to those skilled in the art, and as required by the therapeutic action desired and the limitations of the selected therapeutic agent 105. Association methods include overlayment, absorption, and imbedding, which may be by any method known to those in the art, including spraying, dipping, ion implantation, and painting. Alternative embodiments of the invention may include associating therapeutic agent 105 by impregnation, co-mixing, or absorption into control member 90 in any manner known to those skilled in the art, and as required by therapeutic action desired and the limitations of the selected therapeutic agent 105. Co-mixing includes combining the therapeutic agent 105 with a carrier or the material of control member 90 in such a manner that the therapeutic agent 105 is releasable from the mix. An antimicrobial therapeutic agent 105 may be absorbed into at least a portion of control member 90.


An aspect of the invention and a flow control member, such as control member 90, is directed toward targeted intra-bronchial delivery of a therapeutic agent that treats diseases and conditions of the patient, particularly those associated with the lungs such as inflammatory, infectious, and neoplastic diseases. Treatment of certain lung diseases and conditions will benefit from targeted intra-bronchial delivery of a therapeutic agent 105 into the involved regions. Treatment will be further benefited if the therapeutic agent 105 is generally confined to the involved regions. For example, treatment of pneumonia will benefit by being able to deliver an antibiotic to the specific lung region involve. Treatment will also be benefited by isolating the involved lung portion to prevent disease dissemination. By inhibiting exhalation and/or mucociliary transport, control member 90 meets these treatment goals by generally confining the therapeutic agent to the lung portion, and by isolating the lung portion to prevent disease dissemination. Depending on the course of treatment desired, control member 90 may be arranged to allow the lung portion to be or remain inflated by allowing inhalation airflow and limiting exhalation airflow, or to collapse the lung portion by limiting inhalation airflow.


Still further, the therapeutic agent may be associated with an element of an intra-bronchial device, which in turn is coupled to control member 90. Such elements may include structural members, or anchors for example. The therapeutic agent may be associated with control member 90 either before or after it is inserted into air passageway 50, or renewed after insertion.



FIG. 9 is a longitudinal sectional view illustrating an intra-bronchial device placed in an air passageway 50 for providing a therapeutic agent 105 to a patient, the control member 90 of the intra-bronchial device having a cavity 110 for carrying the therapeutic agent 105, in accordance with the invention. Control member 90 includes a cavity 110 that carries therapeutic agent 105. While the cavity 110 is illustrated in FIG. 9 as cylindrical in configuration, it may be of any shape. Radioactive seeds may be carried in cavity 110. A plurality of intra-bronchial devices may be placed in a lung portion, thus allowing providers to group or cluster the radioactive seeds in a manner similar to that used to treat tumors in other portions of the body, such as prostate, breast, and brain tumors.


In another embodiment, the cavity 110 of control member 90 may include an absorptive member (not shown) that carries the therapeutic agent 105. The absorptive member may occupy all or at least a portion of the cavity 110. The absorptive member may be any material and any configuration known to those skilled in the art, and as required by the limitations of selected therapeutic agent 105.



FIG. 10 illustrates a control member 90 similar to FIG. 9 with a cover 112 having an orifice 114 to regulate release of the therapeutic agent 105, in accordance with the invention. The orifice 114 of cavity cover 112 limits the release of the therapeutic agent 105 from cavity 110. Orifice 114 is sized and located to regulate the release of therapeutic agent from cavity 110.



FIGS. 11-13 illustrate an intra-bronchial device for providing a therapeutic agent 105 with a control member 120 having a one-way valve, in accordance with the invention. FIG. 11 illustrates the control member 120 with the one-way valve in a closed configuration, and FIG. 12 illustrates the one-way valve in an open configuration. Control member 120 includes a structure similar to that described in U.S. Pat. No. 6,293,951, which is owned by the assignee of this application, and which is incorporated herein by reference. However, the control member 120 and one-way valve of the instant invention are structured and arranged when deployed in an air passageway to permit inhalation of air into the lung portion while inhibiting exhalation of air from the lung portion.


The one-way valve may be centrally positioned in the control member 120. Control member 120 includes a generally circular base 134 and a circumferential generally cylindrical sidewall 136. Control member 120 further includes resilient reinforcement rib 130. To form the one-way valve, the base 134 is made from a resilient material, and includes a slit 122 to form a valving structure. On either side of the slit 122 is a tether 124 and 126, which extend to the resilient reinforcement rib 130. As illustrated in FIG. 13, control member 120 is configured for placement in the air passageway 50 so that the one-way valve structure opens to permit inhalation airflow 128 (in the direction indicated by the arrow), and closes to limit exhalation airflow. The therapeutic agent 105 is associated with the control member 120 as described in conjunction with FIG. 8.



FIG. 13 is a longitudinal sectional view illustrating the intra-bronchial device placed in the air passageway 50. The intra-bronchial device may be placed in the air passageway 50 using any method known to those skilled in the art, including the method described in conjunction with FIGS. 3-6. The one-way valve structure opens to permit inspiration airflow 128 (in the direction indicated by the arrow), but limits exhalation airflow. This orientation permits air to be inhaled into the distal lung portion, which may assist in delivering the therapeutic agent 105 to the distal lung portion communicating with the air passageway 50. Conversely, the one-way valve may be arranged to permit exhaustion airflow but preclude inspiration, if advantageous.


The contact between the outer dimension 91 and air passageway inner dimension 51 may be arranged to form a mucus seal stopping or limiting proximal mucus movement. The one-way valve will limit airflow from the lung portion 66 and maintain it in an inflated condition. Any therapeutic agent 105 released distally of control member 90 will be inhibited from moving proximally by the one-way valve and the mucus seal.


An aspect of the invention provides for arranging and carrying therapeutic agent 105 on a distal portion of a control member in a manner to promote intra-bronchial delivery. FIG. 13 illustrates therapeutic agent 105 associated with a distal portion of base 134 of control member 120, which also forms a moveable part of the valve. In this structural arrangement, therapeutic agent 105 is physically exposed to the targeted distal lung portion, and movement of the valve with inhalation 128 and against exhalation may aid release of therapeutic agent 105. The structure of control member 120 will inhibit the released therapeutic agent 105 from moving proximally, although therapeutic agent 105 may move proximal to the control member by escaping through the valve, between the wall 100 and control member 120, or by mucociliary transport.



FIG. 14 is a longitudinal sectional view illustrating an alternative embodiment of the intra-bronchial device of FIGS. 11-13 having a valving mechanism arranged to open when the air pressure in the lung portion reaches a predetermined level and to allow exhalation airflow to prevent over inflation of the lung portion, in accordance with the invention. Control member 130 is substantially similar to control member 120, however, the fixation points of the tethers 124 and 126 has been moved radially away from the slit 122, and the thickness of portions of the base 134 proximate to the slit 122 has been reduced to provide lips 137 and 138. The lips 137 and 138 are arranged to open when the air pressure in the lung portion reaches a predetermined level and to allow exhalation airflow 129 (in the direction indicated by the arrow) to prevent over inflation of the lung portion.



FIGS. 15, 16a, and 16b illustrate an anchored intra-bronchial device 200 for providing a therapeutic agent 105, in accordance with the invention. Intra-bronchial device 200 includes a flow control member 290 and distal anchors carried on a central support structure. FIG. 15 is a side view of the device 200. FIG. 16a illustrates the device 200 placed in an air passageway with an orientation that permits inhalation airflow 128 and inhibits exhalation flow, and FIG. 16b illustrates the device 200 with an orientation that permits exhalation airflow 129 and inhibits inhalation air flow. Anchored and removable intra-bronchial devices are disclosed in co-pending applications “REMOVABLE LUNG REDUCTION DEVICES, SYSTEMS, AND METHODS” filed Sep. 11, 2001, application Ser. No. 09/951,105; “REMOVABLE ANCHORED LUNG VOLUME REDUCTION DEVICES AND METHODS” filed Mar. 20, 2002, application Ser. No. 10/104,487; “REMOVABLE ANCHORED LUNG VOLUME REDUCTION DEVICES AND METHODS” filed Apr. 16, 2002, application Ser. No. 10/124,790; and “REMOVABLE ANCHORED LUNG VOLUME REDUCTION DEVICES AND METHODS” filed May 17, 2002, application Ser. No. 10/150,547, (collectively referred to as “Applications for Anchored Devices”) which are owned by the Assignee, and which are incorporated herein by reference. The Applications for Anchored Devices generally disclose and describe the structure, operation, placement, and removal of anchored intra-bronchial devices, such as intra-bronchial device 200.


The structure of anchored intra-bronchial device 200 includes support structure 201 and a control member 290. Support structure 201 includes a central support structure 209, an anchor base 261, and optionally control member support members 202, 203, 204, 205, 206 and 208. The anchor base 261 includes an anchor base aperture 265, anchor base angle 263, and anchors 212, 214, and 216, which include anchor ends 222, 224, and 226, and stops 252, 254, and 256, respectively. Central support structure 209 extends both proximal and distal of control member 290, and carries anchor base 261 proximal of control member 290. Central support structure 209 also distally carries the cavity 110 that is arranged for carrying the therapeutic agent 105. The linear plane of anchors 212, 214, and 216 intersect anchor base 261 at anchor base angle 263. Anchor base angle 263 is selected to optimize anchor deployment force and anchor releaseability. Stops 252, 254, and 256 include a flat area to limit the piercing of the air passageway wall by anchor ends 222, 224, and 226. In alternative embodiments, the stops can be any configuration or shape known to those skilled in the art to limit the piercing.


The anchors 212, 214, and 216 are arranged to be collapsible into a configuration for being fed through the conduit 70 in a collapsed state, and to move to an anchoring configuration upon deployment in the air passageway 50 for engaging the interior wall of the air passageway 50. The anchors are further arranged to be releaseable from the interior wall of the air passageway by engaging the intra-bronchial device 200 with an instrument, and drawing device 200 into the conduit 70 and removing it from the patient. The Applications for Anchored Devices provide additional descriptions of anchored structures, of anchoring an intra-bronchial device in an air passageway, and of releasing the anchors and removing the intra-bronchial device from an air passageway.


Flow control member 290 is similar to flow control member 90. Flow control member 290 may be formed of a flexible membrane or a solid material, is generally impervious to airflow, and may be formed of a silicone or polyurethane, for example. Flow control member 290 may have any shape suitable for accomplishing its purpose, and optimally is collapsible to enable it to be fed through the conduit 70 in a collapsed state. Control member 290 may either be supported by its own structure, or may be carried on and supported by control member support members, such as members 202, 203, 204, 205, 206 and 208. Control member 290 is arranged to be carried on the support structure 201, and to have its generally circular base orientated distally. Control member 290 is secured to the central support structure 109, and may be additionally secured to the support members at its larger diameter 91. It may be secured by adhesive, or other manner known in the art. Control member 290 may be structurally arranged, or loosely carried on support members 102, 103, 104, 105, 106, and 108, such that it expands radially outwardly when airflow is directed toward the generally circular base 94 to form a seal against the wall of the air passageway 50 and limits air and mucus flow. Control member 290 may be further structurally arranged to contract when the airflow reverses to diminish or break the seal and permit airflow. While FIGS. 15, 16a, and 16b illustrate anchoring an intra-bronchial device 200 having a flow control member 290 that is formed of a flexible membrane, in alternative embodiments, anchoring may be used with any type of intra-bronchial device that provides a therapeutic agent. Furthermore, while FIGS. 15 and 16 illustrate the anchors being carried on a support structure, in alternative embodiments the anchors may be carried on the flow control member or in any other manner associating the anchors with the intra-bronchial device. In further alternative embodiments, the anchors may be positioned distal of the control member and/or proximal of the control member.


Control member 290 may include a separator or filtration element, or semi-permeable membrane, arranged to allow movement of air and water vapor molecules, but to inhibit movement of larger molecules and mucociliary transport. For example, a separator element such as a NUCLEPORE® polycarbonate track etch membrane, a registered trademark of Whatman, Inc., of Newton, Mass., could be used for all or a portion of the control member 290. The molecules of the therapeutic agent 105 are associated with molecules larger than air and water molecules, and the separator is arranged to inhibit movement of the larger associated molecules while allowing movement of the smaller air and water vapor molecules.



FIG. 17 illustrates an assembly of a plurality of intra-bronchial devices 300a-c for providing a therapeutic agent 105 and a flow control member 330 for inhibiting movement of the therapeutic agent 105 proximally, all placed in an air passageway branch, in accordance with the invention. Intra-bronchial device 330 is substantially similar in construction, placement, and operation to intra-bronchial device 120 except that it does not carry a therapeutic agent 105. Intra-bronchial device 300a-c is similar in construction, placement, and operation to intra-bronchial device 120 except the one-way valve structure is omitted. Free passage of air and moisture is permitted past intra-bronchial devices 300 through aperture 310 as depicted by arrow 320. An alternative embodiment of the intra-bronchial devices 300 and 330 may provide for mucociliary transport.


Use of multiple cooperating intra-bronchial devices as illustrated in FIG. 17 may be advantageous in treating and diagnosing certain diseases and conditions, or in certain patients, or when using certain types of intra-bronchial devices. For example, a plurality of intra-bronchial devices may be required or used to provide proper dosing of therapeutic agent 105 to a lung portion. Intra-bronchial devices that do not provide flow control may be more simple to install, may be less expensive to manufacture, and may typically have a smaller outer periphery 91 diameter in a range of 2-3 mm. In addition, the targeted bronchial branches may be too small for placement of an intra-bronchial device that provides flow control, which is presently in the range of 3-5 mm. A plurality of miniature intra-bronchial devices 300 carrying therapeutic agent 105 may be driven distal into the bronchial tree and lung tissue to treat localized disease, down to possibly 2 mm in diameter, or possibly into the bronchioli once smaller devices are developed. Such miniature intra-bronchial devices 300 may be guided by very small diameter bronchoscopes, or other types of high resolution imaging techniques that may include using ancillary catheters and possibly a guidewire. For example, miniature devices could be used to treat a localized fungus disease close to the surface of the lungs, or as a method to place chemotherapy for lung cancer. The therapeutic agent 105 may be localized and confined to the lung portion by an intra-bronchial device 330 placed in a larger air passageway, such as air passageway 42.


Intra-bronchial device 300 may be any member that does not significantly obstruct flow of air. For example, the intra-bronchial device carrying therapeutic agent 105 may be a tubular member coated with therapeutic agent 105, which may be balloon expandable as is known in the art, or may be self-expanding.


Additional intra-bronchial devices and methods for providing a therapeutic agent to a patient are disclosed and claimed in INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Feb. 21, 2002, application Ser. No. 10/081,712; and INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Jun. 21, 2002, application Ser. No. 10/178,073, which are incorporated herein by reference.


While particular embodiments of the present invention have been shown and described, modifications may be made, and it is therefore intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims
  • 1. An intra-bronchial device for maintaining a therapeutic agent within an air passageway, the device comprising: a flow control member arranged for placement in an air passageway and inhibiting the therapeutic agent from moving proximal of the flow control member;at least one anchor associated with the flow control member, the at least one anchor having a linear elongate portion with a first end and second end, the first end of the linear elongate portion coupled to the flow control member, the second end of the linear elongate portion extending away from the flow control member, the linear elongate portion comprising more than one bend configured to allow the at least one anchor to be collapsed for positioning within a delivery catheter; andthe therapeutic agent associated with the flow control member.
  • 2. The intra-bronchial device of claim 1 further comprising an introducer that introduces the therapeutic agent in a lung portion distal of the flow control member.
  • 3. The intra-bronchial device of claim 1, wherein the flow control member inhibits movement of the therapeutic agent by limiting flow from the air passageway.
  • 4. The intra-bronchial device of claim 1, wherein the flow control member inhibits the movement of the therapeutic agent by limiting mucociliary transport from the air passageway.
  • 5. The intra-bronchial device of claim 1, wherein the flow control member includes a one-way valve.
  • 6. The intra-bronchial device of claim 5, wherein the at least one anchor is positioned proximally relative to the one-way valve, and the one-way valve is positioned to permit inhalation of air into the air passageway, and the intra-bronchial device to prevent exhalation of air from the air passageway.
  • 7. The intra-bronchial device of claim 5, wherein the at least one anchor is positioned distally relative to the one-way valve, and the one-way valve is positioned to permit exhalation of air from the air passageway.
  • 8. The intra-bronchial device of claim 1, wherein the flow control member includes a flexible membrane impervious to air flow.
  • 9. The intra-bronchial device of claim 8, wherein the flexible membrane is arranged in cooperation with a wall of the air passageway to form a one-way valve permitting airflow from the air passageway.
  • 10. The intra-bronchial device of claim 8, wherein the flexible membrane is arranged in cooperation with a wall of the air passageway to form a one-way valve permitting airflow into the air passageway.
  • 11. The intra-bronchial device of claim 1, wherein the flow control member includes a separator arranged to inhibit the movement of the therapeutic agent while allowing movement of air.
  • 12. The intra-bronchial device of claim 11, wherein molecules of the therapeutic agent are associated with molecules larger than air molecules, and the separator is arranged to inhibit movement of the associated molecules while allowing movement of air molecules.
  • 13. The intra-bronchial device of claim 1, wherein the flow control member includes a semi-permeable membrane arranged to retain the therapeutic agent distal of the control member while permitting air and water molecules to be exhaled.
  • 14. The intra-bronchial device of claim 1, wherein the flow control member allows airflow from the air passageway sufficiently to prevent over-inflation of a lung portion.
  • 15. The intra-bronchial device of claim 1, wherein the flow control member is further arranged to automatically terminate the inhibiting of movement by the therapeutic agent.
  • 16. The intra-bronchial device of claim 1, wherein the flow control member is further arranged to permit mucociliary transport from the air passageway.
  • 17. The device of claim 1, wherein the therapeutic agent is one of antimicrobial agents such as adrenergic agents, antibiotic agents or antibacterial agents, antiviral agents, anthelmintic agents, anti-inflammatory agents, antineoplastic agents, antioxidant agents, biological reaction inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic agents, gene therapy agents, hormonal agents, mucolytic agents, radioprotective agents, radioactive agents including brachytherapy materials, tissue growth inhibitors, tissue growth enhancers, and vasoactive agents.
  • 18. The intra-bronchial device of claim 1, wherein the linear elongate portion comprises a first portion and a second portion, the second portion forming a substantially perpendicular angle relative to a central axis extending between distal and proximal ends of the device.
  • 19. The intra-bronchial device of claim 1, wherein the flow control member further comprises at least one support member having a curved end for allowing removal of the device.
  • 20. The intra-bronchial device of claim 1 further comprises a central support structure to carry the flow control member, the central support structure configured to extend proximally to allow a removal device to engage and remove the device.
  • 21. The intra-bronchial device of claim 1, wherein the therapeutic agent is carried by the flow control member.
  • 22. The intra-bronchial device of claim 1, wherein the therapeutic agent is absorbed into a portion of the flow control member.
  • 23. The intra-bronchial device of claim 1, wherein the flow control member is configured to prevent exhalation airflow from a lung portion.
  • 24. The intra-bronchial device of claim 1, wherein the flow control member further comprises at least one lip configured to open when air pressure in the lung portion exceeds a threshold level to allow exhalation airflow from the lung portion.
RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 10/317,667 (now U.S. Pat. No. 6,929,637), filed on Dec. 11, 2002, which is a continuation-in-part of and claims priority based on United States applications entitled INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Feb. 21, 2002, application Ser. No. 10/081,712 now abandoned; and INTRA-BRONCHIAL AIRFLOW CONTROL DEVICE THAT CONTROLS BIOLOGICAL INTERACTION WITH THE PATIENT filed Jun. 21, 2002, application Ser. No. 10/178,073 now abandoned. The entire contents of each of the above-noted prior patent applications are hereby incorporated by reference herein and made a part of this specification.

US Referenced Citations (392)
Number Name Date Kind
2479805 Sabaratnam Aug 1949 A
2832078 Williams Apr 1958 A
2981254 Vanderbilt Apr 1961 A
3320972 High et al. May 1967 A
3370305 Goott et al. Feb 1968 A
3445916 Schulte May 1969 A
3472230 Forgarty Oct 1969 A
3540431 Mobin-Uddin Nov 1970 A
3617060 Lezzi Nov 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3683913 Kurtz et al. Aug 1972 A
3757783 Alley Sep 1973 A
3760808 Bleuer Sep 1973 A
3788327 Donowitz et al. Jan 1974 A
3874388 King et al. Apr 1975 A
4014318 Dockum et al. Mar 1977 A
4040428 Clifford Aug 1977 A
4056854 Boretos et al. Nov 1977 A
4084268 Ionescu et al. Apr 1978 A
4086665 Poirier May 1978 A
4212463 Repinski et al. Jul 1980 A
4218782 Rygg Aug 1980 A
4222126 Boretos et al. Sep 1980 A
4250873 Bonnet Feb 1981 A
4301810 Belman Nov 1981 A
4302854 Runge Dec 1981 A
4339831 Johnson Jul 1982 A
RE31040 Possis Sep 1982 E
4403616 King Sep 1983 A
4456016 Nowacki et al. Jun 1984 A
4512338 Balko et al. Apr 1985 A
4533137 Sonne Aug 1985 A
4569674 Phillips et al. Feb 1986 A
4582058 Depel et al. Apr 1986 A
4592741 Vincent Jun 1986 A
4601465 Roy Jul 1986 A
4610256 Wallace Sep 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4654027 Dragan et al. Mar 1987 A
4654029 D'Antonio Mar 1987 A
4681110 Wiktor Jul 1987 A
4684363 Ari et al. Aug 1987 A
4685908 Kurtz Aug 1987 A
4710192 Liotta et al. Dec 1987 A
4727873 Mobin-Uddin Mar 1988 A
4732152 Wallsten et al. Mar 1988 A
4745925 Dietz May 1988 A
4759758 Gabbay Jul 1988 A
4795449 Schneider et al. Jan 1989 A
4808183 Panje Feb 1989 A
4819664 Nazari Apr 1989 A
4822354 Elosegui Apr 1989 A
4830003 Wolff et al. May 1989 A
4832680 Haber et al. May 1989 A
4846836 Reich Jul 1989 A
4850999 Planck Jul 1989 A
4852568 Kensey Aug 1989 A
4877025 Hanson Oct 1989 A
4908028 Colon et al. Mar 1990 A
4934999 Bader Jun 1990 A
4936823 Colvin et al. Jun 1990 A
4968294 Salama Nov 1990 A
4973047 Norell Nov 1990 A
4979505 Cox Dec 1990 A
4984581 Stice Jan 1991 A
5033312 Stupecky Jul 1991 A
5038621 Stupecky Aug 1991 A
5059208 Coe et al. Oct 1991 A
5061274 Kensey Oct 1991 A
5078739 Martin Jan 1992 A
5092781 Casciotti et al. Mar 1992 A
5116360 Pinchuk et al. May 1992 A
5116564 Jansen et al. May 1992 A
5123919 Sauter et al. Jun 1992 A
5135488 Foote et al. Aug 1992 A
5151105 Kwan-Gett Sep 1992 A
5158548 Lau et al. Oct 1992 A
5161524 Evans Nov 1992 A
5171299 Heitzmann et al. Dec 1992 A
5197980 Gorshkov et al. Mar 1993 A
5255687 McKenna Oct 1993 A
5275169 Afromowitz et al. Jan 1994 A
5283063 Freeman Feb 1994 A
5300050 Everett, Jr. et al. Apr 1994 A
5304199 Myers Apr 1994 A
5306234 Johnson Apr 1994 A
5314473 Godin May 1994 A
5339805 Parker Aug 1994 A
5342298 Michaels Aug 1994 A
5352240 Ross Oct 1994 A
5353470 Bartlett Oct 1994 A
5358518 Camilli Oct 1994 A
5366478 Brinkerhoff et al. Nov 1994 A
5370657 Irie Dec 1994 A
5382261 Palmaz Jan 1995 A
5383470 Kolbly Jan 1995 A
5391205 Knight Feb 1995 A
5392775 Adkins, Jr. et al. Feb 1995 A
5398844 Zaslavsky et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5409444 Kensey et al. Apr 1995 A
5411507 Heckele May 1995 A
5411552 Andersen et al. May 1995 A
5413599 Imachi et al. May 1995 A
5415660 Campbell et al. May 1995 A
5417226 Juma May 1995 A
5421325 Cinberg et al. Jun 1995 A
5445626 Gigante Aug 1995 A
5453090 Martinez et al. Sep 1995 A
5459544 Emura Oct 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5486154 Kelleher Jan 1996 A
5499995 Teirstein Mar 1996 A
5500014 Quijano et al. Mar 1996 A
RE35225 Herweck et al. Apr 1996 E
5507754 Green et al. Apr 1996 A
5507797 Suzuki et al. Apr 1996 A
5509900 Kirkman Apr 1996 A
5514153 Bonutti May 1996 A
5549626 Miller et al. Aug 1996 A
5549628 Cooper et al. Aug 1996 A
5562608 Sekins et al. Oct 1996 A
5562641 Flomenblit et al. Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5603698 Roberts et al. Feb 1997 A
5607469 Frey Mar 1997 A
5645565 Rudd et al. Jul 1997 A
5647857 Anderson et al. Jul 1997 A
5660175 Dayal Aug 1997 A
5662713 Andersen et al. Sep 1997 A
5669933 Simon et al. Sep 1997 A
5676671 Inoue Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693089 Inoue Dec 1997 A
5697968 Rogers et al. Dec 1997 A
5702343 Alferness Dec 1997 A
5702409 Rayburn et al. Dec 1997 A
5725519 Penner et al. Mar 1998 A
5752522 Murphy May 1998 A
5752965 Francis et al. May 1998 A
5755770 Ravenscroft May 1998 A
5763979 Mukherjee et al. Jun 1998 A
5782896 Chen et al. Jul 1998 A
5797920 Kim Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800339 Salama Sep 1998 A
5803078 Brauner Sep 1998 A
5810837 Hofmann et al. Sep 1998 A
5817101 Fiedler Oct 1998 A
5830217 Ryan Nov 1998 A
5833694 Poncet Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5851232 Lois Dec 1998 A
5855587 Hyon et al. Jan 1999 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5876434 Flomenblit et al. Mar 1999 A
5876445 Andersen et al. Mar 1999 A
5911756 Debry Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5947997 Pavcnik et al. Sep 1999 A
5954636 Schwartz et al. Sep 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5957978 Blom Sep 1999 A
5972009 Fortier et al. Oct 1999 A
5976158 Adams et al. Nov 1999 A
5976174 Ruiz Nov 1999 A
5984965 Knapp et al. Nov 1999 A
5989234 Valerio et al. Nov 1999 A
6003517 Sheffield et al. Dec 1999 A
6007575 Samuels Dec 1999 A
6009614 Morales Jan 2000 A
6010511 Murphy Jan 2000 A
6010525 Bonutti et al. Jan 2000 A
6020380 Killian Feb 2000 A
6027525 Suh et al. Feb 2000 A
6045560 McKean et al. Apr 2000 A
6051022 Cai et al. Apr 2000 A
6068635 Gianotti May 2000 A
6068638 Makower May 2000 A
6077291 Das Jun 2000 A
6079413 Baran Jun 2000 A
6083141 Hougen Jul 2000 A
6083255 Laufer et al. Jul 2000 A
6096027 Layne Aug 2000 A
6099551 Gabbay Aug 2000 A
6123663 Rebuffat Sep 2000 A
6132458 Staehle et al. Oct 2000 A
6135729 Aber Oct 2000 A
6135991 Muni et al. Oct 2000 A
6141855 Morales Nov 2000 A
6146357 Addis Nov 2000 A
6149664 Kurz Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165179 Cathcart et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6168617 Blaeser et al. Jan 2001 B1
6174307 Daniel et al. Jan 2001 B1
6174323 Briggs et al. Jan 2001 B1
6183520 Pintauro et al. Feb 2001 B1
6193748 Thompson et al. Feb 2001 B1
6200333 Laufer Mar 2001 B1
6203551 Wu Mar 2001 B1
6206918 Campbell et al. Mar 2001 B1
6210338 Afremov et al. Apr 2001 B1
6231587 Makower May 2001 B1
6231589 Wessman et al. May 2001 B1
6234996 Bagaoisan et al. May 2001 B1
6238334 Easterbrook, III et al. May 2001 B1
6240615 Kimes et al. Jun 2001 B1
6241654 Alferness Jun 2001 B1
6241678 Afremov et al. Jun 2001 B1
6241758 Cox Jun 2001 B1
6242472 Sekins et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6258100 Alferness et al. Jul 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6267775 Clerc et al. Jul 2001 B1
6270527 Campbell et al. Aug 2001 B1
6287290 Perkins et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6293951 Alferness et al. Sep 2001 B1
6299604 Ragheb et al. Oct 2001 B1
6302893 Limon et al. Oct 2001 B1
6312407 Zadno-Azizi et al. Nov 2001 B1
6325777 Zadno-Azizi et al. Dec 2001 B1
6325778 Zadno-Azizi et al. Dec 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6328689 Gonzalez et al. Dec 2001 B1
6338728 Valerio et al. Jan 2002 B1
6350278 Lenker et al. Feb 2002 B1
6355014 Zadno-Azizi et al. Mar 2002 B1
6398775 Perkins et al. Jun 2002 B1
6402754 Gonzalez Jun 2002 B1
6416554 Alferness et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6428561 Johansson-Ruden et al. Aug 2002 B1
6439233 Geertsema Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6447530 Ostrovsky et al. Sep 2002 B1
6454754 Frank Sep 2002 B1
6458076 Pruitt Oct 2002 B1
6458153 Bailey et al. Oct 2002 B1
6471718 Staehle et al. Oct 2002 B1
6471979 New et al. Oct 2002 B2
6485407 Alferness et al. Nov 2002 B2
6488673 Laufer et al. Dec 2002 B1
6491706 Alferness et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6503272 Duerig et al. Jan 2003 B2
6510846 O'Rourke Jan 2003 B1
6514290 Loomas Feb 2003 B1
6527761 Buch et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6544192 Starr et al. Apr 2003 B2
6544291 Taylor Apr 2003 B2
6558429 Taylor May 2003 B2
6568387 Davenport et al. May 2003 B2
6569166 Gonzalez May 2003 B2
6585639 Kotmel et al. Jul 2003 B1
6589256 Forber Jul 2003 B2
6592594 Rimbaugh et al. Jul 2003 B2
6599311 Biggs et al. Jul 2003 B1
6600307 Turski et al. Jul 2003 B2
6610043 Ingenito Aug 2003 B1
6629951 Laufer et al. Oct 2003 B2
6632243 Zadno-Azizi et al. Oct 2003 B1
6634363 Laufer et al. Oct 2003 B1
6638285 Gabbay Oct 2003 B2
6669724 Park et al. Dec 2003 B2
6673070 Edwards et al. Jan 2004 B2
6679264 Deem et al. Jan 2004 B1
6682250 Banks Jan 2004 B2
6682520 Ingenito Jan 2004 B2
6694979 Deem et al. Feb 2004 B2
6709401 Perkins et al. Mar 2004 B2
6712812 Roschak et al. Mar 2004 B2
6716208 Humes Apr 2004 B2
6722360 Doshi Apr 2004 B2
6743259 Ginn Jun 2004 B2
6746686 Hughes et al. Jun 2004 B2
6749606 Keast et al. Jun 2004 B2
6840952 Saker et al. Jan 2005 B2
6849049 Starr et al. Feb 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6860847 Alferness et al. Mar 2005 B2
6887256 Gilson May 2005 B2
6904909 Andreas et al. Jun 2005 B2
6929637 Gonzalez et al. Aug 2005 B2
6941950 Wilson et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6958076 Acosta et al. Oct 2005 B2
6989027 Allen et al. Jan 2006 B2
6997951 Solem et al. Feb 2006 B2
7011094 Rapacki et al. Mar 2006 B2
7100616 Springmeyer Sep 2006 B2
7141046 Perkins et al. Nov 2006 B2
7175644 Cooper et al. Feb 2007 B2
7207946 Sirokman Apr 2007 B2
7252086 Tanaka Aug 2007 B2
7278430 Kumar Oct 2007 B2
7357795 Kaji et al. Apr 2008 B2
7412977 Fields et al. Aug 2008 B2
7434578 Dillard et al. Oct 2008 B2
7476203 DeVore et al. Jan 2009 B2
7530995 Quijano et al. May 2009 B2
7533671 Gonzalez et al. May 2009 B2
7757692 Alferness et al. Jul 2010 B2
7798974 Sirokman Sep 2010 B2
7842010 Bonnette et al. Nov 2010 B2
7842061 Dillard et al. Nov 2010 B2
7875048 Dillard et al. Jan 2011 B2
20010010017 Letac et al. Jul 2001 A1
20010025132 Alferness et al. Sep 2001 A1
20010034518 Edwards et al. Oct 2001 A1
20010037808 Deem et al. Nov 2001 A1
20010041906 Gonzalez Nov 2001 A1
20010051799 Ingenito Dec 2001 A1
20010052344 Doshi Dec 2001 A1
20010056274 Perkins et al. Dec 2001 A1
20020007831 Davenport et al. Jan 2002 A1
20020029004 Starr et al. Mar 2002 A1
20020052626 Gilson May 2002 A1
20020062120 Perkins et al. May 2002 A1
20020077564 Campbell et al. Jun 2002 A1
20020077593 Perkins et al. Jun 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020087153 Roschak et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111619 Keast et al. Aug 2002 A1
20020111620 Cooper et al. Aug 2002 A1
20020112729 DeVore et al. Aug 2002 A1
20020123749 Jain Sep 2002 A1
20020138135 Duerig et al. Sep 2002 A1
20020147462 Mair et al. Oct 2002 A1
20030018327 Truckai et al. Jan 2003 A1
20030018344 Kaji et al. Jan 2003 A1
20030024527 Ginn Feb 2003 A1
20030050648 Alferness et al. Mar 2003 A1
20030051733 Kotmel et al. Mar 2003 A1
20030055331 Kotmel et al. Mar 2003 A1
20030070682 Wilson et al. Apr 2003 A1
20030083671 Rimbaugh et al. May 2003 A1
20030109869 Shadduck Jun 2003 A1
20030125763 McInnes Jul 2003 A1
20030127090 Gifford et al. Jul 2003 A1
20030154988 DeVore et al. Aug 2003 A1
20030158515 Gonzalez et al. Aug 2003 A1
20030167065 Kumar Sep 2003 A1
20030180922 Eaton et al. Sep 2003 A1
20030181922 Alferness Sep 2003 A1
20030183235 Rimbaugh et al. Oct 2003 A1
20030195385 DeVore Oct 2003 A1
20030212337 Sirokman Nov 2003 A1
20030212412 Dillard et al. Nov 2003 A1
20030216769 Dillard et al. Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030228344 Fields et al. Dec 2003 A1
20040039250 Tholfsen et al. Feb 2004 A1
20040059263 DeVore Mar 2004 A1
20040127912 Rabkin et al. Jul 2004 A1
20040143282 Dillard et al. Jul 2004 A1
20040167636 Dillard et al. Aug 2004 A1
20040206349 Alferness et al. Oct 2004 A1
20040210248 Gordon et al. Oct 2004 A1
20040211412 Alferness et al. Oct 2004 A1
20040243140 Alferness et al. Dec 2004 A1
20040244802 Tanaka Dec 2004 A1
20050033310 Alferness et al. Feb 2005 A1
20050033344 Dillard et al. Feb 2005 A1
20050096721 Mangin et al. May 2005 A1
20050137611 Escudero et al. Jun 2005 A1
20050145253 Wilson et al. Jul 2005 A1
20050166925 Wilson et al. Aug 2005 A1
20050222580 Gifford et al. Oct 2005 A1
20050267323 Dorros et al. Dec 2005 A1
20060074382 Gonzalez et al. Apr 2006 A1
20060235467 DeVore Oct 2006 A1
20060270940 Tsukashima et al. Nov 2006 A1
20070221230 Thompson et al. Sep 2007 A1
20070225747 Perkins et al. Sep 2007 A1
20080015627 DeVore Jan 2008 A1
20080132989 Snow et al. Jun 2008 A1
20090099530 Adams et al. Apr 2009 A1
20090182369 Gonzalez Jul 2009 A1
20090292262 Adams et al. Nov 2009 A1
20100256714 Springmeyer Oct 2010 A1
20100262071 Kutsko et al. Oct 2010 A1
Foreign Referenced Citations (116)
Number Date Country
2002239759 May 2002 AU
2004263132 Oct 2010 AU
2308186 May 1999 CA
2375752 Jan 2001 CA
2401331 Mar 2001 CA
2408923 Nov 2001 CA
101868199 Oct 2010 CN
10004979 Aug 2000 DE
0665029 Aug 1995 EP
0743071 Nov 1996 EP
1151729 Nov 2001 EP
1157663 Nov 2001 EP
106276 May 2002 EP
1198269 Oct 2009 EP
03 716 212 Dec 2010 EP
2 082 071 Mar 1982 GB
324 729 Nov 1998 GB
2348138 Sep 2000 GB
58-163332 Sep 1983 JP
60-10740 Jan 1994 JP
2003-503162 Jan 2003 JP
2003-533266 Nov 2003 JP
2004-535887 Dec 2004 JP
2005-527297 Sep 2005 JP
3742010 Nov 2005 JP
4387803 Oct 2009 JP
2140211 Oct 1999 RU
852321 Jul 1981 SU
1371700 Feb 1988 SU
1593651 Sep 1990 SU
WO 8809683 Dec 1988 WO
WO 9426175 Nov 1994 WO
WO 9532018 Nov 1995 WO
WO 9634582 Nov 1996 WO
WO 9637167 Nov 1996 WO
WO 9709932 Mar 1997 WO
WO 9713471 Apr 1997 WO
WO 9727893 Aug 1997 WO
WO 9742871 Nov 1997 WO
WO 9744085 Nov 1997 WO
WO 9800840 Jan 1998 WO
WO 9801084 Jan 1998 WO
WO 9819633 May 1998 WO
PCTUS9818366 Sep 1998 WO
WO 9839047 Sep 1998 WO
WO 9844854 Oct 1998 WO
WO 9848706 Nov 1998 WO
WO 9901076 Jan 1999 WO
WO 9913801 Mar 1999 WO
WO 9926692 Jun 1999 WO
WO 9932040 Jul 1999 WO
WO 9942059 Aug 1999 WO
WO 9942161 Aug 1999 WO
WO 9959503 Nov 1999 WO
WO 9964109 Dec 1999 WO
WO 0018329 Apr 2000 WO
WO 0027292 May 2000 WO
WO 0042950 Jul 2000 WO
WO 0051500 Sep 2000 WO
WO 0051510 Sep 2000 WO
WO 0062699 Oct 2000 WO
WO 0078386 Dec 2000 WO
WO 0078407 Dec 2000 WO
WO 0102042 Jan 2001 WO
WO 0103641 Jan 2001 WO
WO 0103642 Jan 2001 WO
WO 0105334 Jan 2001 WO
WO 0110313 Feb 2001 WO
WO 0110314 Feb 2001 WO
WO 0112104 Feb 2001 WO
WO 0113839 Mar 2001 WO
WO 0113908 Mar 2001 WO
WO 0128433 Apr 2001 WO
WO 0130266 May 2001 WO
WO 0137897 May 2001 WO
WO 0145590 Jun 2001 WO
WO 0149213 Jul 2001 WO
WO 0152775 Jul 2001 WO
WO 0154585 Aug 2001 WO
WO 0154625 Aug 2001 WO
WO 0154685 Aug 2001 WO
WO 0166190 Sep 2001 WO
WO 0170114 Sep 2001 WO
WO 0174271 Oct 2001 WO
WO 0187170 Nov 2001 WO
WO 0189366 Nov 2001 WO
WO 0195786 Dec 2001 WO
WO 0205884 Jan 2002 WO
PCTUS0128360 Mar 2002 WO
WO 0222072 Mar 2002 WO
WO 0232333 Apr 2002 WO
WO 0234322 May 2002 WO
WO 0238038 May 2002 WO
WO 0247575 Jun 2002 WO
WO 02056794 Jul 2002 WO
WO 02064045 Aug 2002 WO
WO 02064190 Aug 2002 WO
WO 02069823 Sep 2002 WO
WO 02094087 Nov 2002 WO
WO 03022124 Mar 2003 WO
WO 03030975 Apr 2003 WO
WO 03003946 May 2003 WO
WO 03034927 May 2003 WO
WO 03041779 May 2003 WO
WO 03047468 Jun 2003 WO
WO 03078579 Sep 2003 WO
WO 03088820 Oct 2003 WO
WO 03094996 Nov 2003 WO
WO 03099164 Dec 2003 WO
WO 2004010845 Feb 2004 WO
WO 2004080347 Sep 2004 WO
WO 2004244802 Dec 2004 WO
WO 2005013835 Feb 2005 WO
WO 2007123690 Nov 2007 WO
WO 2009049261 Apr 2009 WO
WO 2010118056 Oct 2010 WO
Related Publications (1)
Number Date Country
20060074382 A1 Apr 2006 US
Continuations (2)
Number Date Country
Parent 10317667 Dec 2002 US
Child 11204383 US
Parent 10081712 Feb 2002 US
Child 10317667 US
Continuation in Parts (1)
Number Date Country
Parent 10178073 Jun 2002 US
Child 10081712 US